Literature DB >> 28068631

MicroRNA-202-3p regulates scleroderma fibrosis by targeting matrix metalloproteinase 1.

Bin Zhou1, Honglin Zhu1, Hui Luo1, Siming Gao1, Xiaodan Dai1, Yisha Li2, Xiaoxia Zuo3.   

Abstract

The leading cause of death in systemic sclerosis (SSc) is the uncontrolled fibrosis in multiple organs. The exact mechanism of fibrosis is not fully clear. Our previous studies using miRNA array analysis indicated that miR-202-3p was increased in SSc lesion skin tissues. Bioinformatics analysis suggested matrix metallopeptidase (MMP) 1 is the target gene of miR-202-3p. Here we confirmed that miR-202-3p was upregulated, and the mRNA and protein expression of MMP1 were significantly decreased in SSc skin tissues and primary fibroblast compared with normal skin. MMP1 expression was inversely correlated with the expression of miR-202-3p. Overexpression of miR-202-3p markedly increased collagen disposition in skin primary fibroblasts, while inhibitor of miR-202-3p decreased it. Furthermore, we demonstrated that MMP1 was a target of miR-202-3p detected by luciferase reporter assay, and played an essential role as a mediator of the biological effects of miR-202-3p in SSc fibrosis. Taken together, these findings suggest that miR-202-3p may function as a novel pro-fibrotic miRNA in SSc by inhibition the expression of MMP1.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Fibrosis; MMP1; Systemic sclerosis; miR-202-3p

Mesh:

Substances:

Year:  2017        PMID: 28068631     DOI: 10.1016/j.biopha.2016.12.080

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  16 in total

Review 1.  Unfolding the pathogenesis of scleroderma through genomics and epigenomics.

Authors:  Pei-Suen Tsou; Amr H Sawalha
Journal:  J Autoimmun       Date:  2017-05-16       Impact factor: 7.094

2.  miR-155 inhibits the formation of hypertrophic scar fibroblasts by targeting HIF-1α via PI3K/AKT pathway.

Authors:  Xue Wu; Jun Li; Xuekang Yang; Xiaozhi Bai; Jihong Shi; Jianxin Gao; Yan Li; Shichao Han; Yijie Zhang; Fu Han; Yang Liu; Xiaoqiang Li; Kejia Wang; Julei Zhang; Zheng Wang; Ke Tao; Dahai Hu
Journal:  J Mol Histol       Date:  2018-05-21       Impact factor: 2.611

Review 3.  Epigenetic Control of Scleroderma: Current Knowledge and Future Perspectives.

Authors:  Pei-Suen Tsou
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

Review 4.  Epigenetics of scleroderma: Integrating genetic, ethnic, age, and environmental effects.

Authors:  Paula S Ramos
Journal:  J Scleroderma Relat Disord       Date:  2019-07-03

5.  miR-202-3p negatively regulates MMP-1 to inhibit the proliferation, migration and invasion of lung adenocarcinoma cells.

Authors:  Yong Li; Huiqin Huang; Xiangli Ye; Zhenghui Huang; Xiangqi Chen; Feng Wu; Tingyan Lin
Journal:  Cell Cycle       Date:  2021-01-25       Impact factor: 4.534

6.  Transforming growth factor-β signaling in systemic sclerosis.

Authors:  Nolan B Ayers; Chen-Ming Sun; Shi-You Chen
Journal:  J Biomed Res       Date:  2018-01-18

Review 7.  The JNK Signaling Pathway in Inflammatory Skin Disorders and Cancer.

Authors:  Manel B Hammouda; Amy E Ford; Yuan Liu; Jennifer Y Zhang
Journal:  Cells       Date:  2020-04-02       Impact factor: 6.600

8.  The roles of neutrophil serine proteinases in idiopathic inflammatory myopathies.

Authors:  Siming Gao; Xiaoxia Zuo; Di Liu; Yizhi Xiao; Honglin Zhu; Huali Zhang; Hui Luo
Journal:  Arthritis Res Ther       Date:  2018-07-05       Impact factor: 5.156

Review 9.  MicroRNAs in Autoimmunity and Hematological Malignancies.

Authors:  Mirco Di Marco; Alice Ramassone; Sara Pagotto; Eleni Anastasiadou; Angelo Veronese; Rosa Visone
Journal:  Int J Mol Sci       Date:  2018-10-12       Impact factor: 5.923

10.  Overexpression of microRNA-202-3p protects against myocardial ischemia-reperfusion injury through activation of TGF-β1/Smads signaling pathway by targeting TRPM6.

Authors:  Hui-Ying Wu; Jian-Li Wu; Zhan-Ling Ni
Journal:  Cell Cycle       Date:  2019-02-27       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.